Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xiaoming Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Histone Deacetylase Inhibitors, Antineoplastic Agents, Histone Deacetylases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City, Public Welfare Technology Applied Research Planning Project of Zhoushan.
Abstract (Originalsprache)
HDAC8 is a therapeutic target with great promise for breast cancer. Here, we reported a novel compound corallorazine D from Nocardiopsis sp. XZB108, selectively inhibited HDAC8 (IC50 = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. Upon additional modifications of corallorazine D, a candidate compound 5k, demonstrated remarkable inhibitory potency against HDAC8 (IC50 = 0.12 ± 0.01 nM), 89-fold superior to PCI-34051. The selectivity of 5k was at least 439-fold, superior to corallorazine D, confirming the efficacy of our modifications. In an orthotopic mouse model of breast cancer, 5k displayed nearly 4-fold superior antitumor activity than SAHA. Furthermore, 5k triggered antitumor immunity by activating T cells. Treatment with 5k significantly increased the proportion of M1 macrophages and decreased the proportion of M2 macrophages (M1/M2 ratio = 2.67 ± 0.25). 5k represents a promising compound for further investigation as a potential treatment for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
- Key Laboratory of Digestive Pathophysiology of Zhejiang Province, the First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
- Hainan Institute of Zhejiang University, Sanya 572025, China.
ORCID-Profile: Jiebin Fang, Zhongjun Ma
Förderung
- National Natural Science Foundation of China
- Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City
- Public Welfare Technology Applied Research Planning Project of Zhoushan
Zitieren
APA
Chen, X., Ding, X., Fang, J., Mao, C., Gong, X., Zhang, Y., Zhang, N., Yan, F., Lou, Y., Chen, Z., Ding, W., & Ma, Z. (2024). Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01438
Vancouver
Chen X, Ding X, Fang J, Mao C, Gong X, Zhang Y, et al. Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01438
BibTeX
@article{Chen2024,
author = {Chen, Xiaoming and Ding, Xia and Fang, Jiebin and Mao, Churu and Gong, Xingzhi and Zhang, Yuxiao and Zhang, Ningjing and Yan, Feihang and Lou, Yijie and Chen, Zhe and Ding, Wanjing and Ma, Zhongjun},
title = {Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01438}
}
EUVIMED